Search clinical trials for: Newly diagnosed multiple myeloma

Total 15848 results

The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Study of CT071 Injection in HRNDMM

High-risk Newly Diagnosed Multiple Myeloma (HRNDMM)
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Dickran Kazandjian, MD
Regeneron Pharmaceuticals

Not yet recruiting

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (IMMUNOPLANT)

Multiple Myeloma

United States
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Jinling Hospital, China

Recruiting

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Newly Diagnosed Multiple Myeloma

China
University of Heidelberg Medical Center
Bristol-Myers Squibb; Sanofi; Wuerzburg University Hospital; KKS Netzwerk

Recruiting

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM)

Multiple Myeloma
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR); Myeloma Canada

Recruiting

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Multiple Myeloma

China
All4Cure
Janssen Scientific Affairs, LLC

Recruiting

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

Multiple Myeloma | Multiple Myeloma Without Mention of Remission

United States
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
Augusta University
Janssen Scientific Affairs, LLC

Not yet recruiting

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Multiple Myeloma | Renal Failure

United States
FengYan Jin

Not yet recruiting

A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment (MRD)

Multiple Myeloma | Minimal Residual Disease
National Cancer Institute (NCI)

Recruiting

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)

United States
FengYan Jin

Not yet recruiting

Dynamic Frailty Assessment for Guiding the Treatment in Older Adults With Newly Diagnosed Multiple Myeloma (DFA)

Multiple Myeloma | Frailty
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
The First Affiliated Hospital with Nanjing Medical...

Recruiting

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Multiple Myeloma

China
PETHEMA Foundation
Janssen Pharmaceutica

Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

High-Risk de Novo Multiple Myeloma

Spain
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. (DILEMMA)

Multiple Myeloma | Daratumumab | Autologous Stem Cell Transplantation | Leukapheresis

Italy
Regeneron Pharmaceuticals

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

Multiple Myeloma

United States, France
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more
University of Heidelberg Medical Center
Sanofi; KKS Netzwerk; Deutsche Studiengruppe Multiples Myelom (DSMM)

Recruiting

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Germany, Austria
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20)

Multiple Myeloma

Australia, Poland, Taiwan, Korea, Republic of, Japan, United Kingdom, Brazil, Mexico, Turkey, Argentina
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
University Hopsital Schleswig Holstein Campus Lübeck

Recruiting

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients (ELIAS)

Newly Diagnosed Multiple Myeloma

Germany
Pfizer

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)

Multiple Myeloma

Japan, Taiwan, Canada, Spain, Australia, Italy, Czechia, Korea, Republic of, France, Greece, Israel, Poland, Germany
Hellenic Society of Hematology
GlaxoSmithKline

Recruiting

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Neoplasms | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Gammopathy, Monoclonal | Haematologic Disease | Neoplasm, Plasma Cell

Greece
University Hospital, Lille
Janssen Pharmaceutica N.V., Belgium

Not yet recruiting

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (IFM2021-01)

Multiple Myeloma
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
The First Affiliated Hospital of Soochow University

Not yet recruiting

Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma
PETHEMA Foundation
Bristol-Myers Squibb; Sanofi; Adknoma; Start from scratch

Not yet recruiting

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide (GEM21menos65)

Newly Diagnosed Multiple Myeloma

Spain
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Belgium, Korea, Republic of, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Czechia, Netherlands, Poland, Switzerland, Germany
PETHEMA Foundation
Janssen-Cilag, S.A.; Celgene-BMS; LIDESEC

Not yet recruiting

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Multiple Myeloma

Spain
Xia Zhongjun
Antengene Corporation

Recruiting

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Mayo Clinic

Recruiting

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Plasma Cell Myeloma

United States
Pfizer

Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

Multiple Myeloma

Japan, Belgium, United States, Netherlands, Australia, Austria, Taiwan, China, Spain, Canada, Israel, Germany, Italy, Czechia, Korea, Republic of, Norway, Finland, France, Sweden, Brazil, Greece, Turkey, United Kingdom, Hungary, Poland, I...
Hellenic Society of Hematology
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Neoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Gammopathy, Monoclonal | Haematologic Disease

Greece
Centre Hospitalier Universitaire de Saint Etienne

Recruiting

Biomarkers in Multiple Myeloma (VESICOM)

Chemotherapy | Newly Diagnosed Multiple Myeloma | Hematological Patients

France
Stichting European Myeloma Network
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Multiple Myeloma

Netherlands, United States, Spain, Belgium, France, Italy, Germany, Japan, Canada, Australia, Sweden, Israel, United Kingdom, Czechia, Greece, Switzerland, Norway
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
PETHEMA Foundation
Janssen, LP; Adknoma Health Research

Recruiting

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Multiple Myeloma | Non-eligible for Autologous Stem Cell Transplantation (ASCT)

Spain
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Multiple Myeloma

China
Hellenic Society of Hematology
Sanofi

Not yet recruiting

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Renal Impairment

Greece
UNC Lineberger Comprehensive Cancer Center
Genzyme, a Sanofi Company

Recruiting

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Cancer | Multiple Myeloma

United States
Cancer Trials Ireland
Sanofi; Dana-Farber Cancer Institute

Recruiting

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)

Multiple Myeloma

Denmark, Ireland
M.D. Anderson Cancer Center

Recruiting

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Myeloma Multiple

United States
The First Affiliated Hospital of Soochow University

Not yet recruiting

A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM

Newly Diagnosed Multiple Myeloma

3

Subscribe